Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapagliflozin/metformin/saxagliptin - AstraZeneca

Drug Profile

Dapagliflozin/metformin/saxagliptin - AstraZeneca

Alternative Names: Dapagliflozin/metformin extended release/saxagliptin; Dapagliflozin/saxagliptin/metformin extended release; Dapaglifozin/metformin hydrochloride/saxagliptin - AstraZeneca; Metformin extended release/dapagliflozin/saxagliptin; Metformin extended release/saxagliptin/dapagliflozin; Metformin hydrochloride, saxagliptin and dapagliflozin - AstraZeneca; Qternmet XR; Qtrilmet; Saxagliptin/metformin extended release/dapagliflozin

Latest Information Update: 18 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Adamantanes; Antihyperglycaemics; Azabicyclo compounds; Benzhydryl compounds; Biguanides; Chlorobenzenes; Dipeptides; Glucosides; Nitriles; Organic bridged compounds; Piperidines; Pyrans; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Type 2 diabetes mellitus

Most Recent Events

  • 15 Nov 2019 Registered for Type 2 diabetes mellitus in European Union, Iceland, Norway, Liechtenstein (PO)
  • 23 Sep 2019 The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopts a positive opinion recommending approval of dapaglifozin/metformin hydrochloride/saxagliptin for Type 2 diabetes mellitus (PO)
  • 03 May 2019 Registered for Type 2 diabetes mellitus in Puerto Rico (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top